Clinical outcomes of COVID-19 infection among patients with Alzheimer's disease or mild cognitive impairment.
Alzheimer's disease
COVID-19
angiotensin II receptor blockers
angiotensin converting enzyme inhibitors
mild cognitive impairment
severe acute respiratory syndrome coronavirus 2
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
23
02
2022
received:
01
09
2021
accepted:
28
02
2022
pubmed:
5
4
2022
medline:
11
5
2022
entrez:
4
4
2022
Statut:
ppublish
Résumé
Alzheimer's disease (AD) and COVID-19 share common risk factors including hypertension. Angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) are frequently prescribed antihypertension medications. This study analyzed 436,823 veterans tested for SARS-CoV-2 infection. We conducted both classical and propensity score weighted logistic models to compare COVID-19 outcomes between patients with AD or mild cognitive impairment (MCI) to those without cognitive impairment, and examined effect of ACEI/ARB prescription. There was a statistically significant association between AD and increased odds of infection and mortality. MCI was not found to be a risk factor for infection. Subjects with MCI exhibited poor clinical outcomes. Prescribing ARBs but not ACEIs was significantly associated with a lower risk of COVID-19 occurrence among AD and MCI patients. Exploring beneficial effects of existing medications to reduce the impact of COVID-19 on patients with AD or MCI is highly significant. There is significant association between Alzheimer's disease (AD) and increased risk of COVID-19 infection and odds of mortality. Subjects with mild cognitive impairment (MCI) defined by claims data exhibit poor clinical outcomes, but MCI was not found to be a risk factor for severe acute respiratory syndrome coronavirus 2 infection. Prescribing angiotensin II receptor blockers was significantly associated with a lower risk of COVID-19 occurrence among AD/MCI patients.
Identifiants
pubmed: 35377523
doi: 10.1002/alz.12665
pmc: PMC9073985
doi:
Substances chimiques
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
911-923Subventions
Organisme : NIA NIH HHS
ID : RF1 AG063913
Pays : United States
Informations de copyright
US Government Published 2022. This article is a U.S. Government work and is in the public domain in the USA.
Références
Brain Sci. 2021 Feb 27;11(3):
pubmed: 33673697
BMJ. 2020 Mar 26;368:m1198
pubmed: 32217618
PLoS One. 2020 Mar 4;15(3):e0229541
pubmed: 32130251
Med Care. 1989 Mar;27(3 Suppl):S178-89
pubmed: 2646488
J Clin Neurosci. 2016 Nov;33:32-38
pubmed: 27475317
Mol Neurobiol. 2021 Jun;58(6):2465-2480
pubmed: 33439437
Alzheimers Res Ther. 2020 Mar 27;12(1):33
pubmed: 32220235
BMJ. 2010 Jan 12;340:b5465
pubmed: 20068258
Alzheimers Dement. 2021 Aug;17(8):1297-1306
pubmed: 33559975
Geriatrics (Basel). 2021 Jan 26;6(1):
pubmed: 33530357
EClinicalMedicine. 2021 Aug;38:101019
pubmed: 34308300
Sci Rep. 2015 Oct 15;5:15015
pubmed: 26468932
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
Neuron. 2015 Jan 21;85(2):296-302
pubmed: 25611508
Alzheimers Dement. 2009 Jul;5(4):348-60
pubmed: 19560105
Epidemiol Rev. 2013;35:161-80
pubmed: 23349428
Alzheimers Res Ther. 2021 Jun 12;13(1):111
pubmed: 34118974
Neurology. 2007 May 22;68(21):1809-14
pubmed: 17515542
Neurobiol Dis. 2017 Nov;107:41-56
pubmed: 27425887
PLoS One. 2021 Mar 18;16(3):e0248652
pubmed: 33735262
Front Neurol. 2021 Jan 20;11:573095
pubmed: 33551947
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
Neurobiol Aging. 2018 Oct;70:70-77
pubmed: 30007166
Immun Ageing. 2014 Dec 05;11(1):22
pubmed: 25516763
Aging health. 2008 Feb 1;4(1):47-55
pubmed: 19924258
J Alzheimers Dis. 2011;26(4):699-708
pubmed: 21709373
Neurobiol Aging. 2015 Oct;36(10):2737-47
pubmed: 26163986
Ann Neurol. 2003 Aug;54(2):267-71
pubmed: 12891684
SN Compr Clin Med. 2020;2(8):1069-1076
pubmed: 32838147
Brain Behav Immun. 2020 Jul;87:95-96
pubmed: 32353523
J Alzheimers Dis. 2020;78(4):1775-1782
pubmed: 33285638
Curr Rev Clin Exp Pharmacol. 2021;16(1):73-78
pubmed: 32003701
Curr Neuropharmacol. 2017;15(7):996-1009
pubmed: 28294067
CNS Neurol Disord Drug Targets. 2014;13(7):1140-7
pubmed: 25230225
Cell Stem Cell. 2021 Feb 4;28(2):331-342.e5
pubmed: 33450186
CMAJ. 2016 Jan 5;188(1):25-32
pubmed: 26504102
Nat Rev Neurol. 2021 Feb;17(2):69-70
pubmed: 33408384
J Gerontol A Biol Sci Med Sci. 2020 Sep 16;75(9):1801-1803
pubmed: 32623451
Alzheimers Dement. 2022 May;18(5):911-923
pubmed: 35377523
J Alzheimers Dis. 2020;77(2):459-504
pubmed: 32925078
J Alzheimers Dis. 2008 May;13(4):437-49
pubmed: 18487851
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
Am J Geriatr Psychiatry. 2020 Jul;28(7):712-721
pubmed: 32331845